



Organization:

Society of Interventional Oncology
2025 M St NW #800, Washington, DC 20036
Phone: (202) 367-1164

Friday, 15 August 2025

NCCN Guidelines Panel:

On behalf of the Society of Interventional Oncology, we respectfully request the NCCN Soft Tissue Sarcoma Panel review the enclosed data for inclusion in the guidelines:

Change Request 1: In SARC-F page 1, Catheter-Directed Therapies, Principles of Interventional Oncology, add references after the statement "TARE utilizes beta particle emitting microspheres by yttrium-90 decay to induce tumoricidal effects through local brachytherapy. TARE can be performed with either glass or resin microspheres." Sarcoma specific studies have reviewed the result of TARE with both glass and resin beta particle emitting microspheres.

References:

- Wenhui Zhou, Liping Du, Daniel B Brown, Rajesh P Shah, Daniel Y Sze. Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry. J Vasc Interv Radiol (2024) 35(11):1591-1600 doi: 10.1016/j.jvir.2024.07.006
- Stefano Testa, Nam Q Bui, David S Wang, John D Louie, Daniel Y Sze, Kristen N Ganjoo. Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas. Cancers (2022) 14(2):324. doi: 10.3390/cancers14020324.

Change Request 2: In SARC-F, Page 2, Ablation, Principles of Interventional Oncology, add a sentence after the sentence "Non-thermal ablation such as irreversible electroporation (IRE) results in permanent cellular membrane injury" stating "Histotripsy uses focused ultrasound in a non-thermal fashion to create cavitation which mechanically disrupts cancerous tissue, rendering it non-viable." Histotripsy is an emerging ablative modality in interventional oncology.

References:

- Ahmad Parvinian, Scott M Thompson, John J Schmitz, Brian T Welch, Rebecca Hibbert, Daniel A Adamo, A Nicholas Kurup. Update on Percutaneous Ablation for Sarcoma. Curr Oncol Rep (2024) Jun;26(6):601-613. doi: 10.1007/s11912-024-01532-7.

Thank you for your consideration of these recommendations.

Sincerely,

Joseph Erinjeri, MD, PhD, Memorial Sloan Kettering Cancer Center
DaeHee Kim, MD, The Warren Alpert Medical School, Brown University
Shilpa Reddy, MD, Hospital of the University of Pennsylvania